(1 - 6 from 14
)
| NDAQ:FRLN | Press Release - Stockhouse
stockhouse.com
Jun 14, — “The ultimate promise of gene therapy is a functional cure,” said Pamela Foulds, MD, Chief Medical Officer of Freeline. › press-releases ›
2nd Hem B Patient Group Begins Dosing in Gene Therapy Trial
hemophilianewstoday.com
Jun 15, — “The ultimate promise of gene therapy is a functional cure,” said Pamela Foulds, MD, chief medical officer of Freeline. › news
First Patient Dosed in Freeline's Dose-Confirmation Trial for ...
www.hemophilia.org
Mar 25, — ... and keep hemophilia B patients in the normal range of Factor IX expression, said Pamela Foulds, MD, Chief Medical Officer of Freeline. › news › first-patient-dosed...
Freeline Announces First Patient Dosed in the Phase 1/2 B ...
www.userwalls.news
Mar 9, — Pamela Foulds, MD, Chief Medical Officer of Freeline, said, We are optimistic that the combination of a low dose (7.7e11 vg/kg) of our ... › ... › Business / Finance
sorted by relevance / date